Literature DB >> 17108147

Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women.

Alfonso J García-Piñeres1, Allan Hildesheim, Rolando Herrero, Matthew Trivett, Marcus Williams, Ivannia Atmetlla, Margarita Ramírez, Maricela Villegas, Mark Schiffman, Ana Cecilia Rodríguez, Robert D Burk, Mariana Hildesheim, Enrique Freer, José Bonilla, Concepción Bratti, Jay A Berzofsky, Ligia A Pinto.   

Abstract

The development of cervical cancer and its precursors are linked to persistent infection with oncogenic types of human papillomavirus (HPV). Host immune responses seem to be determinants of risk for this disease. However, little is known about the immunologic determinants of HPV persistence. Here, we examined the association between lymphoproliferative responses to antigens/mitogens and persistent HPV infection in women older than 45 years. Women included in this study were participants in a 10,000-woman population-based cohort study of cervical neoplasia in Costa Rica. Women older than 45 years and HPV DNA positive at a screening visit were selected as cases (n = 283). We selected a comparably sized control group of HPV DNA-negative women, matched to cases on age and time since enrollment (n = 261). At an additional clinical visit, women were cytologically and virologically rescreened, and cervical and blood specimens were collected. Proliferative responses to phytohemagglutinin (PHA), influenza virus (Flu), and HPV16 virus-like particle (VLP) were lower among women with persistent HPV infection [median counts per minute (cpm): 72,849 for PHA, 1,241 for Flu, and 727 for VLP] than for the control group (median cpm: 107,049 for PHA, 2,111 for Flu, and 2,068 for VLP). The decreases were most profound in women with long-term persistence and were only observed for the oldest age group (>/=65 years). Our results indicate that an impairment in host immunologic responses is associated to persistent HPV infection. The fact that effects were evident for all studied stimuli is suggestive of a generalized effect.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17108147     DOI: 10.1158/0008-5472.CAN-06-2034

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection.

Authors:  Troy J Kemp; Allan Hildesheim; Alfonso García-Piñeres; Marcus C Williams; Gene M Shearer; Ana Cecilia Rodriguez; Mark Schiffman; Robert Burk; Enrique Freer; Jose Bonilla; Rolando Herrero; Ligia A Pinto
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

2.  Comparison of the immune microenvironment of the oral cavity and cervix in healthy women.

Authors:  Carole Fakhry; Morgan A Marks; Robert H Gilman; Lilia Cabrerra; Pablo Yori; Margaret Kosek; Patti E Gravitt
Journal:  Cytokine       Date:  2013-09-07       Impact factor: 3.861

3.  Prevalence of oral HPV infection in the United States, 2009-2010.

Authors:  Maura L Gillison; Tatevik Broutian; Robert K L Pickard; Zhen-you Tong; Weihong Xiao; Lisa Kahle; Barry I Graubard; Anil K Chaturvedi
Journal:  JAMA       Date:  2012-01-26       Impact factor: 56.272

Review 4.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

5.  Vaginal self-swab specimen collection in a home-based survey of older women: methods and applications.

Authors:  Stacy T Lindau; Joscelyn N Hoffmann; Katie Lundeen; Angela Jaszczak; Martha K McClintock; Jeanne A Jordan
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2009-02-09       Impact factor: 4.077

6.  Alterations of T-cell surface markers in older women with persistent human papillomavirus infection.

Authors:  Ana Cecilia Rodríguez; Alfonso J García-Piñeres; Allan Hildesheim; Rolando Herrero; Matthew Trivett; Marcus Williams; Ivannia Atmella; Margarita Ramírez; Maricela Villegas; Mark Schiffman; Robert Burk; Enrique Freer; José Bonilla; Concepción Bratti; Ligia A Pinto
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

7.  Differences in the concentration and correlation of cervical immune markers among HPV positive and negative perimenopausal women.

Authors:  Morgan A Marks; Raphael P Viscidi; Kathryn Chang; Michelle Silver; Anne Burke; Roslyn Howard; Patti E Gravitt
Journal:  Cytokine       Date:  2011-10-19       Impact factor: 3.861

8.  Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention.

Authors:  Seoyoung C Kim; Sarah Feldman; Anna-Barbara Moscicki
Journal:  Rheumatology (Oxford)       Date:  2018-07-01       Impact factor: 7.580

Review 9.  The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer.

Authors:  Theresa Guo; David W Eisele; Carole Fakhry
Journal:  Cancer       Date:  2016-05-06       Impact factor: 6.860

10.  CD83 polymorphisms and cervical cancer risk.

Authors:  Kelly J Yu; Janet S Rader; Ingrid Borecki; Zhengyan Zhang; Allan Hildesheim
Journal:  Gynecol Oncol       Date:  2009-05-15       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.